STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-199)	ELRANATAMAB
PRONUNCIATION	el” ra nat’ a mab
THERAPEUTIC CLAIM	Antineoplastic

CHEMICAL NAMES

1. Immunoglobulin G2 [224-arginine,265-alanine,330-serine,331-serine], anti-(human CD3 antigen ε-chain) (human-*Mus musculus* monoclonal PF-06863059 γ2-chain), disulfide with human-*Mus musculus* monoclonal PF-06863059 κ-chain, (223→217')(227→221')(230→224')-tris(disulfide) with immunoglobulin G2 [218-glutamic acid,259-alanine,324-serine,325-serine] anti-(human B-cell maturation antigen) (human monoclonal PF-06863058 γ2-chain) disulfide with human monoclonal PF-06863058 κ-chain (Source: CAS)

2. Immunoglobulin G2-kappa, anti-(*Homo sapiens* T-cell surface glycoprotein CD3 epsilon chain *CD3E* (T-cell surface antigen T3/Leu-4 epsilon chain)), human-*Mus musculus* monoclonal disulfide with immunoglobulin G2-kappa, anti-(*Homo sapiens* - Tumor necrosis factor receptor superfamily member 17 *TNR17* (B-cell maturation protein; CD269_antigen)), human-*Mus musculus* monoclonal disulfide with immunoglobulin G2-kappa. γ2 heavy chain anti-*CD3E* (1-447) [*Homo sapiens* VH (IGHV3-48*03 (84%) –(IGHD)-IGHJ4*01 (86%)) [8.10.12] (1-121) -*Homo sapiens* IGHG2*01 {hinge[C^{5}>R(224),E^{7}>R(226),P^{10}>R(229)], CH2[D^{35}>A(265), A^{100}>S(330),P^{101}>S(331)], CH3[K^{69}>R(409)]} (122-447)] (135-219')-disulfide with κ light chain anti-*CD3E* (1'-219') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (90%)-IGKJ2*02 (91%)/*Mus musculus* IGKV8-21*01 (84%)-IGKJ4*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (223-217'':227-221'':230-224'')-trisdisulfide with γ2 heavy chain anti-*TNR17* (1''-441'') [*Homo sapiens* VH (IGHV3-23*01 (94%) –(IGHD)-IGHJ1*01) [8.8.8] (1''-115'') -*Homo sapiens* IGHG2*01 {hinge[C^{5}>E(218''),P^{10}>E(223'')], CH2[D^{35}>A(259''),A^{100}>S(324''),P^{101}>S(325'')], CH3[L^{28}>E(362'')]} (116''-441'') (129''-215''')-disulfide with κ light chain anti-*TNR17* (1'''-215''') [*Homo sapiens* V-KAPPA (*Homo sapiens* IGKV3-20*01 (95%) –IGKJ1*01)[7.3.9] (1'''-108''') -*Homo sapiens* IGKC*01 (109'''-215''') (Source: USAN Program Chemical Consultant)

STRUCTURAL FORMULA

Heavy chain anti-CD3E

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	DYYMTWVRQA	PGKGLEWVAF	50
IRNRARGYTS	DHNPSVKGRF	TISRDNAKNS	LYLQMNSLRA	EDTAVYYCAR	100
DRPSYYVLDY	WGQGTTVTVS	SASTKGPSVF	PLAPCSRSTS	ESTAALGCLV	150
KDYFPEPVTV	SWNSGALTSG	VHTFPAVLQS	SGLYSLSSVV	TVPSSNFGTQ	200
TYTCNVDHKP	SNTKVDKTVE	RKCRVRCPRC	PAPPVAGPSV	FLFPPKPKDT	250
LMISRTPEVT	CVVVAVSHED	PEVQFNWYVD	GVEVHNAKTK	PREEQFNSTF	300
RVVSVLTVVH	QDWLNGKEYK	CKVSNKGLPS	SIEKTISKTK	GQPREPQVYT	350
LPPSREEMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	YKTTPPMLDS	400
DGSFFLYSRL	TVDKSRWQQG	NVFSCSVMHE	ALHNHYTQKS	LSLSPGK	447

Light chain anti-CD3E

DIVMTQSPDS	LAVSLGERAT	INCKSSQSLF	NVRSRKNYLA	WYQQKPGQPP	50'
KLLISWASTR	ESGVPDRFSG	SGSGTDFTLT	ISSLQAEDVA	VYYCKQSYDL	100'
FTFGSGTKLE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150'
VQWKVDNALQ	SGNSQESVTE	QDSKDSTYSL	SSTLTLSKAD	YEKHKVYACE	200'
VTHQGLSSPV	TKSFNRGEC				219'

Heavy chain anti-TNR17

EVQLLESGGG	LVQPGGSLRL	SCAASGFTFS	SYPMSWVRQA	PGKGLEWVSA	50''
IGGSGGSLPY	ADIVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCARYW	100''
PMDIWGQGTL	VTVSSASTKG	PSVFPLAPCS	RSTSESTAAL	GCLVKDYFPE	150''
PVTVSWNSGA	LTSGVHTFPA	VLQSSGLYSL	SSVVTVPSSN	FGTQTYTCNV	200''
DHKPSNTKVD	KTVERKCEVE	CPECPAPPVA	GPSVFLFPPK	PKDTLMISRT	250''
PEVTCVVVAV	SHEDPEVQFN	WYVDGVEVHN	AKTKPREEQF	NSTFRVVSVL	300''
TVVHQDWLNG	KEYKCKVSNK	GLPSSIEKTI	SKTKGQPREP	QVYTLPPSRE	350''
EMTKNQVSLT	CEVKGFYPSD	IAVEWESNGQ	PENNYKTTPP	MLDSDGSFFL	400''
YSKLTVDKSR	WQQGNVFSCS	VMHEALHNHY	TQKSLSLSPG	K	441''

Light chain anti-TNR17

EIVLTQSPGT	LSLSPGERAT	LSCRASQSVS	SSYLAWYQQK	PGQAPRLLMY	50'''
DASIRATGIP	DRFSGSGSGT	DFTLTISRLE	PEDFAVYYCQ	QYQSWPLTFG	100'''
QGTKVEIKRT	VAAPSVFIFP	PSDEQLKSGT	ASVVCLLNNF	YPREAKVQWK	150'''
VDNALQSGNS	QESVTEQDSK	DSTYSLSSTL	TLSKADYEKH	KVYACEVTHQ	200'''
GLSSPVTKSF	NRGEC				215'''

Disulfide bridges location

22''-96''	22-98	23'''-89'''	23'-94'	135'''-195'''	139'-199'
142''-198''	148-204	215'''-129''	219'-135	217''-223	221''- 227
224''-230	255''-315''	261-321	361''-419''	367-425	

Glycosylation sites (N)

Asn-291'' Asn-297

MOLECULAR FORMULA	$C_{6440}H_{9958}N_{1738}O_{2010}S_{49}$
MOLECULAR WEIGHT	145.46 kDa (before post-translational modifications)
TRADEMARK	None as yet
SPONSOR	Pfizer
CODE DESIGNATIONS	PF-06863135, RN613
CAS REGISTRY NUMBER	2408850-14-4
UNII	L0HR9A577V
WHO NUMBER	11838

gbk